Answers are grounded in this paper and cite their sources.
In non-advanced systemic mastocytosis (SM), mast cells (MC) express CD2 and CD58 and form focal tissue-aggregates, whereas in advanced SM, MC often lack CD2 and produce diffuse infiltration. To explore the role of CD2 in SM progression, CD2 + and CD2 − subclones of HMC-1.2 cells were generated and injected intraperitoneally into pfp/rag2 mice and scid mice. CD2 + HMC-1.2 cells formed focal MC lesions in the peritoneum and lungs of pfp/rag2 mice, while CD2 − HMC-1.2 cells produced more diffuse infiltration, resulting in reduced survival. To explore the mechanisms of organ invasion, E- and P-selectin-deficient scid mice (scid-select) were employed. While infiltrates of CD2 + and CD2 − HMC-1.2 cells were detected in scid mice, organ-infiltration was markedly reduced or absent in scid-select mice. Moreover, scid-select mice injected with CD2 + or CD2 − HMC-1.2 cells showed prolonged survival compared to control mice (p < 0.01). Correspondingly, CD2 was expressed more frequently on MC in patients with non-advanced SM compared to advanced SM, and patients with CD2 + SM were found to have prolonged survival compared to patients with CD2 − SM (p < 0.05). Together, E- and P-selectins mediate organ-invasion of neoplastic MC, whereas loss of CD2 contributes to a diffuse leukemic spread of MC and thus SM progression with reduced survival.
No takes yet. Share an insight, caveat, or question.
Valent et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: